Constructing "high-risk women": The development and standardization of a breast cancer risk assessment tool
Constructing "high-risk women": The development and standardization of a breast cancer risk assessment tool
复制标题
DOI：
10.1177/0162243904264960
复制
发表时间：
2004-06-01
影响因子：
3.1
通讯作者：
Fosket, J
中科院分区：
文献类型：
--
作者：
Fosket, J
最近，两种处方药（他莫昔芬和雷洛昔芬）已成为突出的乳腺癌预防。随着这些被称为“化学预防”的药物的出现，出现了一项任务，即将某些妇女列为乳腺癌高风险人群，以确定这些药物的合法使用者。本文探讨的发展和标准化的模型，用于创建这样一个高风险的妇女群体。作者认为，虽然该模型仍然存在不确定性和争议，但它已成为美国许多与合法化化学预防使用相关的工作的标准嘟嘟声。它已成为假定的标准，塑造的做法，身份和定义，通过其组织嵌入在多种做法和公众形象的化学预防，尽管它的不确定性和广泛的批评。
Recently, two prescription drugs (tamoxifen and raloxifene) have become salient to breast cancer prevention. With the advent of these drugs, referred to as "chemoprevention," a mandate has emerged to classify certain women as high risk for breast cancer to determine a group of legitimate users of the drugs. This article examines the development and standardization of the model used to create such a group of high-risk women. The author argues that while the model remains uncertain and controversial, it has become the standard toot for the many jobs associated with legitimizing chemoprevention use in the United States. It has become the assumed standard-shaping practices, identities, and definitions-through its organizational embeddedness in the multiple practices and public images of chemoprevention despite its uncertainty and widespread critique.